×
About 5,576 results

ALLMedicine™ Chronic Myelogenous Leukemia Center

Research & Reviews  2,591 results

RAG enhances BCR-ABL1 positive leukemic cell growth through its endonuclease activity i...
https://doi.org/10.1111/cas.14939
Cancer Science; Yuan M, Wang Y et. al.

May 5th, 2021 - BCR-ABL1 gene fusion associated with additional DNA lesions involves to the pathogenesis of chronic myelogenous leukemia (CML) from a chronic phase (CP) to a blast crisis of B lymphoid (CML-LBC) lineage and BCR-ABL1+ acute lymphoblastic leukemia (...

Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogen...
https://doi.org/10.1038/s41388-021-01799-1 10.1182/blood-2008-07-077958 10.1038/leu.2015.36 10.1126/scitranslmed.3009073 10.1182/blood-2016-09-696013 10.1038/nrc3317 10.1007/s11912-018-0665-2 10.1056/NEJMoa1306494 10.1016/S2352-3026(15)00127-1 10.1182/blood-2002-09-2780 10.1002/sctm.18-0247 10.1016/j.canlet.2012.08.006 10.1038/nature18288 10.1126/scitranslmed.aag1180 10.1038/ng.389 10.1158/1078-0432.CCR-16-1298 10.1172/JCI85239 10.1158/2159-8290.CD-15-1439 10.1016/j.ccr.2007.11.003 10.1038/nature07737 10.1038/nrd.2016.256 10.1101/gad.2027411 10.1101/gad.1284005 10.1038/s41419-018-0322-6 10.1186/1476-4598-13-189 10.1038/s41591-019-0499-y 10.1038/s41467-017-00350-9 10.1016/j.jhep.2017.05.015 10.1101/gad.236794.113 10.1021/jm401480r 10.1016/j.ccell.2018.09.001 10.1038/ng.2350 10.3389/fimmu.2015.00487 10.1016/j.semcancer.2019.07.011 10.1073/pnas.1901639116 10.1158/0008-5472.CAN-18-2676 10.1038/onc.2015.234 10.1038/nrg.2016.93 10.1158/1535-7163.MCT-16-0567-T 10.18632/oncotarget.11256 10.1038/s41419-017-0120-6 10.1186/s12943-017-0596-9 10.18632/oncotarget.3159 10.1016/j.radonc.2017.03.002 10.1038/s41467-018-07077-1 10.1007/s11010-014-2077-4 10.1182/blood-2010-04-282350 10.1158/0008-5472.CAN-17-1733 10.1158/1078-0432.CCR-17-1533
Oncogene Zhou M, Zhang X et. al.

May 1st, 2021 - The application of tyrosine kinase inhibitors (TKIs) in clinic has revolutionized chronic myelogenous leukemia (CML) treatment, but fails to eliminate leukemia stem cells (LSCs), which are considered as roots of drug resistance and disease relapse...

Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular...
https://doi.org/10.1002/hep.31865
Hepatology (Baltimore, Md.); Ishikawa T, Sasaki R et. al.

Apr 26th, 2021 - Portopulmonary hypertension (PoPH) is a subcategory of pulmonary arterial hypertension (PAH) associated with portal hypertension (PH). Certain drugs, including dasatinib, a tyrosine kinase inhibitor (TKI) for chronic myelogenous leukemia, have bee...

One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p1...
https://doi.org/10.5858/arpa.2020-0454-OA
Archives of Pathology & Laboratory Medicine; Martinez RJ, Kang Q et. al.

Mar 26th, 2021 - Quantification and detection of the t(9;22) (BCR-ABL1) translocation in chronic myelogenous leukemia and B-lymphoblastic leukemia are important for directing treatment protocols and monitoring disease relapse. However, quantification using traditi...

Chronic Myelogenous Leukemia in Childhood.
https://doi.org/10.1007/s11912-021-01025-x 10.1200/JCO.2015.66.2866 10.1016/S2352-3026(15)00048-4. 10.1111/bjh.16241 10.1182/blood-2015-06-648667. 10.1007/s00277-015-2322-2. 10.1038/s41375-020-0776-2. 10.1182/blood-2016-03-643544. 10.1016/j.ejca.2019.03.020 10.1038/s41375-018-0157-2 10.1182/blood-2012-06-436782 10.1038/nrc3343. 10.1038/leu.2012.288. 10.1007/s12094-017-1751-x 10.1002/pbc.27422. 10.1016/S1471-4914(02)02305-5 10.1002/pbc.27827. 10.1182/blood.2018882233 10.1200/JCO.2010.32.7114 10.1002/pbc.23031. 10.1038/s41375-018-0179-9 10.1182/bloodadvances.2019001329 10.1200/JCO.2017.75.9597 10.1182/blood.2019000069 10.1182/blood-2016-09-739086. 10.1016/S1470-2045(16)00080-2. 10.1016/j.critrevonc.2017.10.002. 10.1111/bjh.16338 10.1016/j.ejca.2020.05.020 10.1016/j.bbmt.2018.09.029. 10.1111/bjh.12977 10.1002/ajh.25792 10.1056/NEJMoa1902328 10.1182/blood-2019-122623 10.1002/pbc.24521. 10.1111/bjh.16388 10.1111/bjh.16083 10.1200/JCO.2015.62.4718 10.1200/JCO.2017.76.4647 10.1016/j.ejca.2014.10.007 10.1182/blood.V124.21.522.522. 10.1002/pbc.23389. 10.1002/pbc.24121. 10.1002/pbc.22945. 10.1111/bjh.15633 10.1002/pbc.24397 10.1080/08880018.2019.1689320. 10.1038/leu.2009.150 10.1136/bmjopen-2019-030092. 10.1002/pbc.26028 10.1038/s41598-019-39134-0. 10.1056/NEJM200411113512024 10.1007/s11523-017-0521-6. 10.1183/13993003.00217-2017. 10.1182/bloodadvances.2018028035 10.1016/j.ijcard.2019.10.036. 10.1182/bloodadvances.2018025874 10.1161/CIRCULATIONAHA.108.776831. 10.1182/blood-2011-04-347575 10.1182/asheducation-2016.1.170 10.1016/j.leukres.2012.10.021. 10.1016/j.ejon.2020.101730.
Current Oncology Reports; Smith SM, Hijiya N et. al.

Mar 15th, 2021 - Chronic myelogenous leukemia (CML) is rare in children, requiring extrapolation from treatment of adults. In this review, we explore similarities and differences between adult and pediatric CML with a focus on therapeutic advances and emerging cli...

see more →

Guidelines  9 results

JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myel...
https://doi.org/10.1007/s12185-017-2330-1
International Journal of Hematology; Usui N

Sep 24th, 2017 - JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).|2017|Usui N,|administration & dosage,administration & dosage,administration & dosage,administration &...

Chronic Myelogenous Leukemia, Version 1.2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234105
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Radich JP et. al.

Nov 14th, 2013 - The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring m...

Chronic myelogenous leukemia.
https://doi.org/10.6004/jnccn.2012.0009
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Abboud CN et. al.

Jan 9th, 2012 - Chronic myelogenous leukemia.|2012|O'Brien S,Abboud CN,Akhtari M,Altman J,Berman E,|therapeutic use,diagnosis,drug therapy,therapy,therapeutic use,

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
https://doi.org/10.6004/jnccn.2009.0065
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Berman E et. al.

Nov 2nd, 2009 - NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.|2009|O'Brien S,Berman E,Borghaei H,Deangelo DJ,Devetten MP,|therapeutic use,diagnosis,drug therapy,surgery,

Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance muta...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607559
The Journal of Molecular Diagnostics : JMD; Jones D, Kamel-Reid S et. al.

Dec 19th, 2008 - The BCR-ABL tyrosine kinase produced by the t(9;22)(q34;q11) translocation, also known as the Philadelphia chromosome, is the initiating event in chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). Targeting of BCR-ABL with ...

see more →

Drugs  35 results see all →

Clinicaltrials.gov  2,787 results

RAG enhances BCR-ABL1 positive leukemic cell growth through its endonuclease activity i...
https://doi.org/10.1111/cas.14939
Cancer Science; Yuan M, Wang Y et. al.

May 5th, 2021 - BCR-ABL1 gene fusion associated with additional DNA lesions involves to the pathogenesis of chronic myelogenous leukemia (CML) from a chronic phase (CP) to a blast crisis of B lymphoid (CML-LBC) lineage and BCR-ABL1+ acute lymphoblastic leukemia (...

Busulfan - busulfan injection, solution, concentrate-Athenex Pharmaceutical Division, LLC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5eb97384-3dc0-4172-9ffc-693be91077dc

May 2nd, 2021 - Busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan is an alkylating drug indicated for...

Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogen...
https://doi.org/10.1038/s41388-021-01799-1 10.1182/blood-2008-07-077958 10.1038/leu.2015.36 10.1126/scitranslmed.3009073 10.1182/blood-2016-09-696013 10.1038/nrc3317 10.1007/s11912-018-0665-2 10.1056/NEJMoa1306494 10.1016/S2352-3026(15)00127-1 10.1182/blood-2002-09-2780 10.1002/sctm.18-0247 10.1016/j.canlet.2012.08.006 10.1038/nature18288 10.1126/scitranslmed.aag1180 10.1038/ng.389 10.1158/1078-0432.CCR-16-1298 10.1172/JCI85239 10.1158/2159-8290.CD-15-1439 10.1016/j.ccr.2007.11.003 10.1038/nature07737 10.1038/nrd.2016.256 10.1101/gad.2027411 10.1101/gad.1284005 10.1038/s41419-018-0322-6 10.1186/1476-4598-13-189 10.1038/s41591-019-0499-y 10.1038/s41467-017-00350-9 10.1016/j.jhep.2017.05.015 10.1101/gad.236794.113 10.1021/jm401480r 10.1016/j.ccell.2018.09.001 10.1038/ng.2350 10.3389/fimmu.2015.00487 10.1016/j.semcancer.2019.07.011 10.1073/pnas.1901639116 10.1158/0008-5472.CAN-18-2676 10.1038/onc.2015.234 10.1038/nrg.2016.93 10.1158/1535-7163.MCT-16-0567-T 10.18632/oncotarget.11256 10.1038/s41419-017-0120-6 10.1186/s12943-017-0596-9 10.18632/oncotarget.3159 10.1016/j.radonc.2017.03.002 10.1038/s41467-018-07077-1 10.1007/s11010-014-2077-4 10.1182/blood-2010-04-282350 10.1158/0008-5472.CAN-17-1733 10.1158/1078-0432.CCR-17-1533
Oncogene Zhou M, Zhang X et. al.

May 1st, 2021 - The application of tyrosine kinase inhibitors (TKIs) in clinic has revolutionized chronic myelogenous leukemia (CML) treatment, but fails to eliminate leukemia stem cells (LSCs), which are considered as roots of drug resistance and disease relapse...

Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular...
https://doi.org/10.1002/hep.31865
Hepatology (Baltimore, Md.); Ishikawa T, Sasaki R et. al.

Apr 26th, 2021 - Portopulmonary hypertension (PoPH) is a subcategory of pulmonary arterial hypertension (PAH) associated with portal hypertension (PH). Certain drugs, including dasatinib, a tyrosine kinase inhibitor (TKI) for chronic myelogenous leukemia, have bee...

One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p1...
https://doi.org/10.5858/arpa.2020-0454-OA
Archives of Pathology & Laboratory Medicine; Martinez RJ, Kang Q et. al.

Mar 26th, 2021 - Quantification and detection of the t(9;22) (BCR-ABL1) translocation in chronic myelogenous leukemia and B-lymphoblastic leukemia are important for directing treatment protocols and monitoring disease relapse. However, quantification using traditi...

see more →

News  145 results

A 70-Year-Old Man With Splenomegaly: Osmosis USMLE Study Question
https://www.medscape.com/viewarticle/893938_2

Aug 6th, 2020 - Massive splenomegaly is most characteristic of chronic myelogenous leukemia (CML) and hairy cell leukemia (HCL). CML is a neoplastic proliferation of mature myeloid cells, whereas HCL is a neoplastic proliferation of mature B cells. TRAP staining ...

Pyoderma Gangrenosum Developing After Chest Tube Placement in a Patient With Chronic Lymphocytic Leukemia
https://www.mdedge.com/dermatology/article/213731/wounds/pyoderma-gangrenosum-developing-after-chest-tube-placement-patient/page/0/1?channel=45

Dec 6th, 2019 - Comment Pathogenesis of PG Pyoderma gangrenosum lies in the spectrum of neutrophilic dermatoses, which are characterized histologically by a pandermal neutrophilic infiltrate without evidence of an infectious cause or true vasculitis. Clinically,.

Atraumatic splenic rupture as an initial presentation of chronic myelogenous leukemia
https://www.mdedge.com/hematology-oncology/article/137089/leukemia-myelodysplasia-transplantation/atraumatic-splenic
Eric Frost et al

Mar 17th, 2018 - Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm associated with the fusion of the BCR gene located on chromosome 22 and the ABL1 gene on chromosome 9. The fusion results in a reciprocal translocation between chromosomes 9 and 2.

Drug could improve treatment of CML, team says
https://www.mdedge.com/hematology-oncology/article/185091/leukemia-myelodysplasia-transplantation/drug-could-improve-treatment-cml
HT Staff

Mar 7th, 2018 - Lab mouse A microRNA-targeting drug could improve the effectiveness of tyrosine kinase inhibitors (TKIs) against chronic myelogenous leukemia (CML), according to preclinical research published in Nature Medicine. The drug, miristen, targets miR-12.

CHMP backs bosutinib for newly diagnosed CML
https://www.mdedge.com/hematology-oncology/article/185107/leukemia-myelodysplasia-transplantation/chmp-backs-bosutinib-newly-diagnosed
HT Staff

Feb 28th, 2018 - Image by Difu Wu CML cells The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approved use of bosutinib (BOSULIF) to include treatment of patients with newly diagnosed, chronic phase.

see more →

Patient Education  9 results see all →